IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Novocure Limited, & Advises Investors with Losses to...
December 20 2016 - 3:26PM
Business Wire
Lundin Law PC, a shareholder rights firm, announces that it is
investigating claims against Novocure Limited (“Novocure” or the
“Company”) (Nasdaq: NVCR) concerning possible violations of federal
securities laws.
To get more information about this investigation, please contact
Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via
email at brian@lundinlawpc.com.
Novocure creates and markets treatment for solid tumor cancers
therapy called the tumor treating fields (“TTFields”). Novocure
advertises its proprietary therapy, TTFields delivery system,
through the Optune name as a monotherapy treatment for adult
patients with glioblastoma brain cancer.
Novocure revealed that its new Optune prescriptions dropped to
657 in the second quarter from 755 in the first. Asaf Danziger,
Chief Executive Officer of Novocure, stated “[w]hile barriers to
full adoption remain, I am optimistic we will overcome the
challenges inherent in bringing a completely new therapy into
widespread clinical use.”
When this information was revealed to the public, Novocure’s
stock fell over 29%, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities
litigator based in Los Angeles dedicated to upholding shareholders’
rights.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161220005982/en/
Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile:
888-713-1125brian@lundinlawpc.comhttp://lundinlawpc.com/
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Sep 2023 to Sep 2024